Windtree Therapeutics Inc (WINT)

[califax]

$ 4.00



Pipeline Overview

http://www.discoverylabs.com/poverview.php

Discovery Labs is developing its novel, fully synthetic KL4 Surfactant platform with the intent to create a completely new therapeutic approach for the treatment of respiratory disease.


Neonatology

Product introduction begins with anticipated US FDA approval of SURFAXIN® (lucinactant), a liquid instillate formulation of KL4 Surfactant, for Respiratory Distress Syndrome (RDS) in premature infants.

Discovery Labs is developing multiple product solutions for RDS, supporting KL4 Surfactant delivery through a variety of dosage forms, including SURFAXIN LS™, a lyophilized formulation of KL4 Surfactant as well as AEROSURF®, aerosolized KL4 Surfactant. AEROSURF® represents a transformational approach toward neonatal respiratory critical care by potentially reducing or eliminating complications associated with mechanical ventilation.

Additional Respiratory Applications

Discovery Labs is also advancing KL4 Surfactant development in other respiratory disease areas. Key areas of interest include Mucociliary Clearance Dysfunction, a condition which is common to many respiratory diseases; Respiratory Critical Care Spectrum disorders, which include Acute Respiratory Failure (ARF), Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS); and the use of our KL4 Surfactant as an aerosol liposomal system enabling a novel Drug Delivery mechanism for complex pharmaceutical compounds.